WASHINGTON, Oct. 9 -- National Institutes of Health has issued a notice called: Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof.
The notice was published in the Federal Register on Oct. 9 by Surekha Vathyam, Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.
Summary: The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Korea National Institute of Health, lo...